Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fatty Liver

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44396   clinical trials with a EudraCT protocol, of which   7408   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    181 result(s) found for: Fatty Liver. Displaying page 4 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-000685-15 Sponsor Protocol Number: AXA1125-101 Start Date*: 2021-10-18
    Sponsor Name:Axcella Health, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fi...
    Medical condition: Noncirrhotic, Nonalcoholic Steatohepatitis and Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005411-16 Sponsor Protocol Number: NASH-EX-1114 Start Date*: 2015-06-30
    Sponsor Name:Exalenz Bioscience Ltd.
    Full Title: Clinical Study of the BreathID® System to train the algorithm for the 13C-Octanoate Breath Test with or without the 13C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histol...
    Medical condition: Patients with Non-Alcoholic Fatty Liver Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001539-10 Sponsor Protocol Number: UX007-CL302 Start Date*: 2022-12-27
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patient...
    Medical condition: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10077951 Fatty acid oxidation disorder PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000975-18 Sponsor Protocol Number: M13-397 Start Date*: 2012-09-26
    Sponsor Name:Abbott Laboratories GmbH
    Full Title: Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects with Nonalcoholic Steatohepatitis (NASH) and no...
    Medical condition: Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000705-86 Sponsor Protocol Number: 01-2020 Start Date*: 2020-04-26
    Sponsor Name:VALL HEBRON UNIVERSITY HOSPITAL
    Full Title: Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2: randomized clinical trial COVID-19
    Medical condition: Critically ill adult patients with parenteral nutrition and respiratory infection by SARS-COV-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003048-63 Sponsor Protocol Number: MK-3655-001 Start Date*: 2020-12-21
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed) SE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004754-15 Sponsor Protocol Number: 3152-201-002 Start Date*: 2017-06-05
    Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc
    Full Title: Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH)
    Medical condition: Liver fibrosis in Subjects with Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) ES (Prematurely Ended) HU (Prematurely Ended) AT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003107-29 Sponsor Protocol Number: N°005 Start Date*: 2015-08-07
    Sponsor Name:GALMED Pharmaceuticals LTD.
    Full Title: A Phase IIb, double blind, randomized controlled clinical trial to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic- Steatohepatitis (NASH).
    Medical condition: Non-alcoholic Steatohepatitis in patients with two additional features of metabolic syndrome -overweight or obesity and Diabetes Mellitus type II or pre-diabetes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Ongoing) LT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006424-18 Sponsor Protocol Number: EC/2006/117/PGMS Start Date*: 2007-03-01
    Sponsor Name:University of Surrey
    Full Title: THE EFFECT OF RIMONABANT ON ENERGY EXPENDITURE, FATTY ACID METABOLISM, TRIACYLGLYCEROL METABOLISM AND BODY FAT DISTRIBUTION
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005136-30 Sponsor Protocol Number: MK-6024-001 Start Date*: 2021-08-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease
    Medical condition: Nonalcoholic Fatty Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10082249 Nonalcoholic fatty liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004515-56 Sponsor Protocol Number: hepatology_MT_2007-08 Start Date*: 2008-04-28
    Sponsor Name:Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, MUG
    Full Title: Efficacy of ursodeoxycholic acid in the treatment of insulin resistance and vascular dysfunction in non-alcoholic fatty liver disease
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001677-15 Sponsor Protocol Number: 08/H0808/2 Start Date*: 2008-07-21
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: The effect of intraoperative N-acetylcysteine on hepatocellular injury during laparoscopic bariatric surgery. A randomised controlled trial.
    Medical condition: Non-Alcoholic Fatty Liver Disease in patients undergoing weight-loss (bariatric) surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031743 Other chronic nonalcoholic liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001156-55 Sponsor Protocol Number: C1171002 Start Date*: 2017-11-24
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-Weeks To...
    Medical condition: Nonalcoholic Fatty Liver Disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002489-11 Sponsor Protocol Number: GS-US-321-0106 Start Date*: 2013-02-26
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects w...
    Medical condition: Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003172-32 Sponsor Protocol Number: MASH Start Date*: 2018-05-23
    Sponsor Name:Imperial College London
    Full Title: Maraviroc Add-On Therapy for Steatohepatitis in HIV – The MASH Study
    Medical condition: Non alcoholic steatohepatitis (NASH) in patients with HIV mono-infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000295-42 Sponsor Protocol Number: GFT505-212-7 Start Date*: 2012-09-11
    Sponsor Name:GENFIT
    Full Title: A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).
    Medical condition: Patients with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003430-85 Sponsor Protocol Number: OBERAL Start Date*: 2017-11-29
    Sponsor Name:Helsinki University Hospital
    Full Title: A randomized, open, parallel design study to evaluate the effect on liver fat, adipose tissue and metabolic parameters when switching a protease inhibitor or efavirenz to once daily raltegravir in ...
    Medical condition: Study subjects are HIV infected patients with BMI>25kg/m2 and who have at least one metabolic syndrome component or a fatty liver disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-002984-24 Sponsor Protocol Number: PHS-Px-104-II-01 Start Date*: 2013-10-07
    Sponsor Name:Phenex Pharmaceuticals AG
    Full Title: A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10019805 - Hepatobiliary disorders 10024670 Liver disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004775-39 Sponsor Protocol Number: C2541013 Start Date*: 2020-08-21
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINI...
    Medical condition: BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGE 2 OR 3
    Disease: Version SOC Term Classification Code Term Level
    27.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis LLT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-004336-35 Sponsor Protocol Number: IDN-6556-12 Start Date*: 2016-05-20
    Sponsor Name:Conatus Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 03 19:04:28 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA